![Andrew Justin Radcliffe Porter](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew Justin Radcliffe Porter
Directeur Technique/Scientifique/R&D chez Elasmogen Ltd.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Caroline Barelle | M | - |
Elasmogen Ltd.
![]() Elasmogen Ltd. Pharmaceuticals: MajorHealth Technology Elasmogen Ltd. develops soloMER products for treatment of auto-immune mediated and inflammatory diseases. The company is headquartered in Aberdeen, the United Kingdom. | - |
Jane Elizabeth Dancer | M | 61 |
Elasmogen Ltd.
![]() Elasmogen Ltd. Pharmaceuticals: MajorHealth Technology Elasmogen Ltd. develops soloMER products for treatment of auto-immune mediated and inflammatory diseases. The company is headquartered in Aberdeen, the United Kingdom. | 2 ans |
Keith Barclay | M | - |
Elasmogen Ltd.
![]() Elasmogen Ltd. Pharmaceuticals: MajorHealth Technology Elasmogen Ltd. develops soloMER products for treatment of auto-immune mediated and inflammatory diseases. The company is headquartered in Aberdeen, the United Kingdom. | - |
Iain Mackay | M | 62 |
University of Aberdeen
| - |
Moir Lockhead | M | - |
University of Aberdeen
| - |
Bryan Harvey Bodek | M | 71 |
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 15 ans |
David Archibald MacFarlane | M | 67 |
University of Aberdeen
| - |
Paul Grant Ellis | M | 67 |
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 11 ans |
Anne Minto | F | 70 |
University of Aberdeen
| - |
Savvas Neophytou | M | 52 |
Elasmogen Ltd.
![]() Elasmogen Ltd. Pharmaceuticals: MajorHealth Technology Elasmogen Ltd. develops soloMER products for treatment of auto-immune mediated and inflammatory diseases. The company is headquartered in Aberdeen, the United Kingdom. | - |
Max Robinson | M | - |
University of Aberdeen
| - |
Ian Townsend | M | 69 |
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 13 ans |
Neva Haites | M | - |
University of Aberdeen
| 20 ans |
Roger G. Pertwee | M | - |
University of Aberdeen
| - |
Malcolm Barratt-Johnson | M | 61 |
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 4 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Royaume-Uni | 15 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Andrew Justin Radcliffe Porter
- Réseau Personnel